drospirenone and ethinyl estradiol NDC 68462-720

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-720Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0720Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-720-29	68462072029	3 BLISTER PACK in 1 CARTON (68462-720-29) / 1 KIT in 1 BLISTER PACK (68462-720-84)Marketed from Aug 17, 2015

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): drospirenone and ethinyl estradiol
Generic name (nonproprietary): drospirenone and ethinyl estradiol
Dosage form: Kit
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 204296
Marketing start: Aug 17, 2015
Listing expires: Dec 31, 2027
Identifiers: Product ID 68462-720_69e71801-eff9-4165-8a4a-09bef29e0f3fSPL ID 69e71801-eff9-4165-8a4a-09bef29e0f3fSPL set ID 0f8f8a21-cee8-462f-98b3-6c06f2f33e0dRxCUI 630734, 748797, 748798UPC 0368462720295

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N468462072029 followed by a unit qualifier and the quantity

Package 68462-0720-29. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 29, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Drospirenone and ethinyl estradiol tablets are a combination of drospirenone, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) • Treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control. ( 1.3 ) 1.1 Oral Contraceptive Drospirenone and ethinyl estradiol tablets are indicated for use by females of reproductive potential to prevent pregnancy. 1.2 Premenstrual Dysphoric Disorder (PMDD) …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 204296

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 204296
Product	Strength	Form · route	Labeler	Product NDC
drospirenone and ethinyl estradiol	—	Kit	Proficient Rx LP	71205-144
drospirenone and ethinyl estradiol	—	Kit	A-S Medication Solutions	50090-2594